agilon health, inc.
AGL
$3.53
-$0.01-0.28%
Weiss Ratings | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D- | |||
Reward Grade | E | |||
Rating Factors | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Fair | |||
Efficiency Index | Very Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 0.20 | |||
Price History | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -2.75% | |||
30-Day Total Return | -0.56% | |||
60-Day Total Return | 59.73% | |||
90-Day Total Return | 31.23% | |||
Year to Date Total Return | 83.85% | |||
1-Year Total Return | -38.93% | |||
2-Year Total Return | -85.50% | |||
3-Year Total Return | -83.14% | |||
5-Year Total Return | -- | |||
52-Week High % Change | -54.20% | |||
52-Week Low % Change | 136.00% | |||
Price | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $7.73 | |||
52-Week Low Price | $1.50 | |||
52-Week Low Price (Date) | Nov 18, 2024 | |||
52-Week High Price (Date) | Jul 17, 2024 | |||
Valuation | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 1.46B | |||
Enterprise Value | 1.10B | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.64 | |||
Earnings Per Share Growth | -2.81% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 0.24 | |||
Price/Book (Q) | 3.10 | |||
Enterprise Value/Revenue (TTM) | 0.18 | |||
Price | $3.53 | |||
Enterprise Value/EBITDA (TTM) | -4.25 | |||
Enterprise Value/EBIT | -3.89 | |||
Market Cap Category | Small Cap | |||
Dividends and Shares | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 412.04M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | (562) 256-3800 | |||
Address | 440 Polaris Parkway Westerville, OH 43082 | |||
Website | www.agilonhealth.com | |||
Country | United States | |||
Year Founded | 2016 | |||
Profitability | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -4.68% | |||
Profit Margin | -4.29% | |||
Management Effectiveness | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -10.21% | |||
Return on Equity | -- | |||
Income Statement | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 6.05B | |||
Total Revenue (TTM) | 6.06B | |||
Revenue Per Share | $14.71 | |||
Gross Profit (TTM) | 4.84M | |||
EBITDA (TTM) | -259.49M | |||
EBIT (TTM) | -283.96M | |||
Net Income (TTM) | -260.15M | |||
Net Income Avl. to Common (TTM) | -260.15M | |||
Total Revenue Growth (Q YOY) | 44.16% | |||
Earnings Growth (Q YOY) | 36.32% | |||
EPS Diluted (TTM) | -0.64 | |||
EPS Diluted Growth (Q YOY) | 54.54% | |||
Balance Sheet | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 399.97M | |||
Cash Per Share (Q) | $0.97 | |||
Total Current Assets (Q) | 1.46B | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 470.95M | |||
Current Ratio (Q) | 1.265 | |||
Book Value Per Share (Q) | $1.14 | |||
Total Assets (Q) | 1.73B | |||
Total Current Liabilities (Q) | 1.15B | |||
Total Debt (Q) | 43.96M | |||
Total Liabilities (Q) | 1.26B | |||
Total Common Equity (Q) | 470.95M | |||
Cash Flow | AGL - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 139.89M | |||
Cash from Financing (TTM) | -2.58M | |||
Net Change in Cash (TTM) | 79.53M | |||
Levered Free Cash Flow (TTM) | -32.09M | |||
Cash from Operations (TTM) | -57.78M | |||